Clinical Trial Update: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update shows that Cabaletta Bio's experimental therapy CABA-201 is being evaluated in Phase 1/2 studies for generalized myasthenia gravis, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• CABA-201

Snippet

Sponsor: Cabaletta Bio | Conditions: Generalized Myasthenia Gravis (gMG) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING